世衛(wèi)組織啟動"團結(jié)試驗+"

The World Health Organization (WHO) on Wednesday announced that it will test three new drugs for COVID-19, which will involve thousands of researchers at more than 600 hospitals in 52 countries.

當(dāng)?shù)貢r間8月11日，世衛(wèi)組織宣布將新增測試3種藥物，用于治療新冠肺炎。這項測試將在全球52個國家的600余座醫(yī)院內(nèi)進行。

According to a press release issued by WHO on Wednesday, the three new drugs are artesunate, a treatment for severe malaria; imatinib, a drug for certain cancers; and infliximab, a treatment for immune system disorders such as Crohn's Disease.

世衛(wèi)組織在8月11日的新聞稿中稱，3種藥物分別是用于治療嚴(yán)重瘧疾的青蒿琥酯、用于治療某種癌癥的藥物伊馬替尼、以及用于治療免疫系統(tǒng)紊亂如克羅恩病的英夫利西單抗。

These therapies were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients, and they were donated for the trial by their manufacturers, WHO said.

這些藥物是由一個獨立專家小組根據(jù)其在降低新冠肺炎住院患者死亡風(fēng)險方面的潛力選擇的，藥物由制造商為試驗捐贈。

"Finding more effective and accessible therapeutics for COVID-19 patients remains a critical need, and WHO is proud to lead this global effort," said WHO Director-General Tedros Adhanom Ghebreyesus.

世衛(wèi)組織總干事譚德塞說："為新冠肺炎患者找到更多有效和可獲得的治療方法仍然是一項關(guān)鍵需求，世衛(wèi)組織為領(lǐng)導(dǎo)這一全球努力感到自豪。"